Converged avenues: depression and Alzheimer’s disease– shared pathophysiology and novel therapeutics

Bajaj, Shivanshu; Mahesh, Radhakrishnan

doi:10.1007/s11033-023-09170-1

Cited by 6 publications

(2 citation statements)

References 261 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The application of DPN led to a decline in the levels of ROS, alongside a reduction in the expression of caspase-3 and Bax (Bernaud et al, 2022). On the other hand, there was an elevation in the manifestation of the antiapoptotic protein Bcl (Bajaj & Mahesh, 2024). An improvement in the phosphorylation of AKt and ERK1/2 was observed in the treatment DPN (Cummings et al, 2021).…”

Section: Targeting Ersmentioning

confidence: 96%

Estrogen signalling and Alzheimer's disease: Decoding molecular mechanisms for therapeutic breakthrough

Rishabh,

Rohilla,

Bansal

et al. 2024

Eur J of Neuroscience

View full text Add to dashboard Cite

In females, Alzheimer's disease (AD) incidences increases as compared to males due to estrogen deficiency after menopause. Estrogen therapy is the mainstay therapy for menopause and associated complications. Estrogen, a hormone with multifaceted physiological functions, has been implicated in AD pathophysiology. Estrogen plays a crucial role in amyloid precursor protein (APP) processing and overall neuronal health by regulating various factors such as brain‐derived neurotrophic factor (BDNF), intracellular calcium signalling, death domain‐associated protein (Daxx) translocation, glutamatergic excitotoxicity, Voltage‐Dependent Anion Channel, Insulin‐Like Growth Factor 1 Receptor, estrogen‐metabolising enzymes and apolipoprotein E (ApoE) protein polymorphisms. All these factors impact the physiology of postmenopausal women. Estrogen replacement therapies play an important treatment strategy to prevent AD after menopause. However, use of these therapies may lead to increased risks of breast cancer, venous thromboembolism and cardiovascular disease. Various therapeutic approaches have been used to mitigate the effects of estrogen on AD. These include hormone replacement therapy, Selective Estrogen Receptor Modulators (SERMs), Estrogen Receptor Beta (ERβ)‐Selective Agonists, Transdermal Estrogen Delivery, Localised Estrogen Delivery, Combination Therapies, Estrogen Metabolism Modulation and Alternative Estrogenic Compounds like genistein from soy, a notable phytoestrogen from plant sources. However, mechanism via which these approaches modulate AD in postmenopausal women has not been explained earlier thoroughly. Present review will enlighten all the molecular mechanisms of estrogen and estrogen replacement therapies in AD. Along‐with this, the association between estrogen, estrogen‐metabolising enzymes and ApoE protein polymorphisms will also be discussed in postmenopausal AD.

show abstract

Section: Targeting Ersmentioning

confidence: 96%

Estrogen signalling and Alzheimer's disease: Decoding molecular mechanisms for therapeutic breakthrough

Rishabh,

Rohilla,

Bansal

et al. 2024

Eur J of Neuroscience

View full text Add to dashboard Cite

show abstract

“…[9,10]. The situation is further complicated by the overlap of symptoms with those of other neurodegenerative conditions [11][12][13][14][15][16]. Although advances in imaging techniques and biomarker identification have improved the ability to detect brain alterations [17,18], these tools have limitations related to cost, availability, and sometimes invasiveness.…”

Section: Introductionmentioning

confidence: 99%

EEG Data Analysis Techniques for Precision Removal and Enhanced Alzheimer’s Diagnosis: Focusing on Fuzzy and Intuitionistic Fuzzy Logic Techniques

Versaci,

La Foresta

2024

Signals

View full text Add to dashboard Cite

Effective management of EEG artifacts is pivotal for accurate neurological diagnostics, particularly in detecting early stages of Alzheimer’s disease. This review delves into the cutting-edge domain of fuzzy logic techniques, emphasizing intuitionistic fuzzy systems, which offer refined handling of uncertainties inherent in EEG data. These methods not only enhance artifact identification and removal but also integrate seamlessly with other AI technologies to push the boundaries of EEG analysis. By exploring a range of approaches from standard protocols to advanced machine learning models, this paper provides a comprehensive overview of current strategies and emerging technologies in EEG artifact management. Notably, the fusion of fuzzy logic with neural network models illustrates significant advancements in distinguishing between genuine neurological activity and noise. This synthesis of technologies not only improves diagnostic accuracy but also enriches the toolset available to researchers and clinicians alike, facilitating earlier and more precise identification of neurodegenerative diseases. The review ultimately underscores the transformative potential of integrating diverse computational techniques, setting a new standard in EEG analysis and paving the way for future innovations in medical diagnostics.

show abstract

Comprehensive review on single-cell RNA sequencing: A new frontier in Alzheimer's disease research

Jin,

Pei,

Roy

et al. 2024

Ageing Research Reviews

View full text Add to dashboard Cite

Converged avenues: depression and Alzheimer’s disease– shared pathophysiology and novel therapeutics

Cited by 6 publications

References 261 publications

Estrogen signalling and Alzheimer's disease: Decoding molecular mechanisms for therapeutic breakthrough

Estrogen signalling and Alzheimer's disease: Decoding molecular mechanisms for therapeutic breakthrough

EEG Data Analysis Techniques for Precision Removal and Enhanced Alzheimer’s Diagnosis: Focusing on Fuzzy and Intuitionistic Fuzzy Logic Techniques

Comprehensive review on single-cell RNA sequencing: A new frontier in Alzheimer's disease research

Contact Info

Product

Resources

About